CLP1将tRNA代谢与渐进的运动神经元损失联系在一起
Toshikatsu Hanada1, Stefan Weitzer, Barbara Mair
1IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna 1030, Austria.
Nature
|March 12, 2013
概括
激酶CLP1对于运动神经元的生存至关重要. 它的损失导致运动神经元死亡和,产生激活p53的有毒RNA片段,导致细胞死亡.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 活体内CLP1 (RNA激酶) 的功能仍然不清楚.
- 哺乳动物RNA激酶在细胞过程中起着至关重要的作用.
研究的目的:
- 阐明CLP1在运动神经元中的体内功能.
- 研究CLP1依赖的运动神经元退化背后的分子机制.
主要方法:
- 基因酶死亡的Clp1 (Clp1(K/K)) 小鼠的生成.
- 在运动神经元中进行转基因救援实验.
- 对RNA处理和p53激活的分析.
主要成果:
- Clp1 ((K/K) 的小鼠表现出渐进的运动神经元损失,轴突退化和运动功能受损.
- 失去CLP1活动导致异常的铁素转移前RNA处理和小RNA片段的积累.
- 这些RNA片段诱导氧化压力依赖的p53激活和细胞死亡.
- 基因失活p53拯救了Clp1(K/K) 小鼠的运动神经元损失和.
结论:
- CLP1对于运动神经元的维护和功能至关重要.
- 异常的tRNA处理和随后的p53激活是CLP1缺乏引起的运动神经元死亡的关键机制.
- 在这种途径中,p53起到关键调节者的作用,提供了潜在的治疗点.
相关概念视频
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

